BioElectronics Announces Conference Call to Update Investors on Growth I...(ch is approved by Health Canada forthe r...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
BioElectronics Announces Conference Call to Update Investors on Growth Initiatives
Date:5/15/2008
ch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's Food and Drug Administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class II pulsed electromagnetic medical device as have numerous other international regulatory agencies. Information on ActiPatch and BioElectronics Corporation is available at the following websites:
-- U.S. Consumer http://www.actipatchonline.com
-- Podiatry: http://www.pemfpodiatry.com
-- Plastic Surgery: http://www.plasticsurgeryrelief.com and
-- German orthopedic foot & ankle: http://www.diesfussexperten.de
-- Italy and Switzerland: http://www.actipatch.it
-- Canada: http://www.actipatchpaintherapy.ca
-- Netherlands: http://www.actipatch.de
-- Singapore & Malaysia: http://www.astonixlife.com/
-- BioElectronics Corp: http://www.bioelectronicscorp.com
Safe Harbor Statement
This news release contains forward-looking statements related to future
growth and earnings opportunities. Such statements are based upon certain
assumptions and assessments made by management in light of current
conditions, expected future developments and other factors it believes to
be appropriate. Actual results may differ as a result o
'/>"/>
| SOURCE BioElectronics Corporation Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. BioElectronics Corporation Announces Singapore and Malaysia Sales
2. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
3. BioElectronics Announces Canadian Retail Product Launch
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. BioElectronics Corporation Receives Major Orders From Italian Distributor
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3AEterna Zentaris Announces Appointment of New Board Member 2Waters Ships First Units of SYNAPT G2 Mass Spectrometer 2
[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain[0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease[0] AEterna Zentaris Announces Appointment of New Board Member[0] Waters Ships First Units of SYNAPT G2 Mass Spectrometer
Other Biology Technology:Pfizer-Pharmacia Fallout Gives Celltech A CEO 2The Milkweed Effect: Disseminating Technology to New Regions 2The Milkweed Effect: Disseminating Technology to New Regions 3The Milkweed Effect: Disseminating Technology to New Regions 4
Breaking Biology News(10 mins):ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Studying hair of ancient Peruvians answers questions about stress 2Carnegie Mellon researchers receive grant 2Hill Rom Holdings Inc Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast 5793 1Hill Rom Holdings Inc Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast 5793 2OC Based Charity Teams with International Relief Organization in Holiday Fundraising Drive 5791 1OC Based Charity Teams with International Relief Organization in Holiday Fundraising Drive 5791 2Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 1Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 2Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 3Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 4
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |